164 related articles for article (PubMed ID: 37496662)
21. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
22. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
23. An international randomised controlled trial to compare TARGeted Intraoperative radioTherapy (TARGIT) with conventional postoperative radiotherapy after breast-conserving surgery for women with early-stage breast cancer (the TARGIT-A trial).
Vaidya JS; Wenz F; Bulsara M; Tobias JS; Joseph DJ; Saunders C; Brew-Graves C; Potyka I; Morris S; Vaidya HJ; Williams NR; Baum M
Health Technol Assess; 2016 Sep; 20(73):1-188. PubMed ID: 27689969
[TBL] [Abstract][Full Text] [Related]
24. Conversion of non-inferiority margin from hazard ratio to restricted mean survival time difference using data from multiple historical trials.
Chen R; Basu S; Meyers JP; Shi Q
Stat Methods Med Res; 2022 Oct; 31(10):1819-1844. PubMed ID: 35642291
[TBL] [Abstract][Full Text] [Related]
25. Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD).
Yamashita T; Masuda N; Saji S; Araki K; Ito Y; Takano T; Takahashi M; Tsurutani J; Koizumi K; Kitada M; Kojima Y; Sagara Y; Tada H; Iwasa T; Kadoya T; Iwatani T; Hasegawa H; Morita S; Ohno S
Trials; 2020 May; 21(1):391. PubMed ID: 32381018
[TBL] [Abstract][Full Text] [Related]
26. Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99.
Pagani O; Klingbiel D; Ruhstaller T; Nolè F; Eppenberger S; Oehlschlegel C; Bernhard J; Brauchli P; Hess D; Mamot C; Munzone E; Pestalozzi B; Rabaglio M; Aebi S; Ribi K; Rochlitz C; Rothgiesser K; Thürlimann B; von Moos R; Zaman K; Goldhirsch A;
Ann Oncol; 2017 Feb; 28(2):305-312. PubMed ID: 27998961
[TBL] [Abstract][Full Text] [Related]
27. Optimal sample size allocation for two-arm superiority and non-inferiority trials with binary endpoints.
Kirchner M; Schüpke S; Kieser M
Pharm Stat; 2024 Mar; ():. PubMed ID: 38471740
[TBL] [Abstract][Full Text] [Related]
28. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
Weir IR; Trinquart L
Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
[TBL] [Abstract][Full Text] [Related]
29. A conceptual framework for cautious escalation of anticancer treatment: How to optimize overall benefit and obviate the need for de-escalation trials.
Pourmir I; Van Halteren HK; Elaidi R; Trapani D; Strasser F; Vreugdenhil G; Clarke M
Cancer Treat Rev; 2024 Mar; 124():102693. PubMed ID: 38330752
[TBL] [Abstract][Full Text] [Related]
30. A regulatory perspective on choice of margin and statistical inference issue in non-inferiority trials.
Hung HM; Wang SJ; O'Neill R
Biom J; 2005 Feb; 47(1):28-36; discussion 99-107. PubMed ID: 16395994
[TBL] [Abstract][Full Text] [Related]
31. When inferiority meets non-inferiority: implications for interim analyses.
Bratton DJ; Williams HC; Kahan BC; Phillips PP; Nunn AJ
Clin Trials; 2012 Oct; 9(5):605-9. PubMed ID: 22796636
[TBL] [Abstract][Full Text] [Related]
32. Superiority and non-inferiority: two sides of the same coin?
Dunn DT; Copas AJ; Brocklehurst P
Trials; 2018 Sep; 19(1):499. PubMed ID: 30223881
[TBL] [Abstract][Full Text] [Related]
33. Testing of non-inferiority and superiority for three-arm clinical studies with multiple experimental treatments.
Zhong J; Wen MJ; Kwong KS; Cheung SH
Stat Methods Med Res; 2018 Jun; 27(6):1751-1765. PubMed ID: 27647816
[TBL] [Abstract][Full Text] [Related]
34. Handling an uncertain control group event risk in non-inferiority trials: non-inferiority frontiers and the power-stabilising transformation.
Quartagno M; Walker AS; Babiker AG; Turner RM; Parmar MKB; Copas A; White IR
Trials; 2020 Feb; 21(1):145. PubMed ID: 32029000
[TBL] [Abstract][Full Text] [Related]
35. Trial designs and results supporting treatment de-escalation and escalation.
Regan MM; Barry WT
Breast; 2017 Aug; 34 Suppl 1():S10-S12. PubMed ID: 28673539
[TBL] [Abstract][Full Text] [Related]
36. NORAD01-GRECCAR16 multicenter phase III non-inferiority randomized trial comparing preoperative modified FOLFIRINOX without irradiation to radiochemotherapy for resectable locally advanced rectal cancer (intergroup FRENCH-GRECCAR- PRODIGE trial).
Brouquet A; Bachet JB; Huguet F; Karoui M; Artru P; Sabbagh C; Lefèvre JH; Vernerey D; Mariette C; Vicaut E; Benoist S;
BMC Cancer; 2020 May; 20(1):485. PubMed ID: 32471382
[TBL] [Abstract][Full Text] [Related]
37. Non-inferiority trials in breast and non-small cell lung cancer: choice of non-inferiority margins and other statistical aspects.
Saad ED; Buyse M
Acta Oncol; 2012 Sep; 51(7):890-6. PubMed ID: 22974094
[TBL] [Abstract][Full Text] [Related]
38. The Smooth Away From Expected (SAFE) non-inferiority frontier: theory and implementation with an application to the D3 trial.
Quartagno M; Chan M; Turkova A; Ford D; White IR
Trials; 2023 Aug; 24(1):556. PubMed ID: 37626423
[TBL] [Abstract][Full Text] [Related]
39. Modified Haybittle-Peto group sequential designs for testing superiority and non-inferiority hypotheses in clinical trials.
Lai TL; Shih MC; Zhu G
Stat Med; 2006 Apr; 25(7):1149-67. PubMed ID: 16189814
[TBL] [Abstract][Full Text] [Related]
40. The Sinai Robotic Surgery Trial in HPV-related oropharyngeal squamous cell carcinoma (SIRS 2.0 trial) - study protocol for a phase II non-randomized non-inferiority trial.
Chai RL; Ferrandino RM; Barron C; Donboli K; Roof SA; Khan MN; Teng MS; Posner MR; Bakst RL; Genden EM
Front Oncol; 2022; 12():965578. PubMed ID: 36091121
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
